[DXR] Daxor Corporation


Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.


Price: 8.65 Change: 0.15 (1.76%)
Ext. hours: Change: 0 (0%)

chart DXR

Refresh chart

Strongest Trends Summary For DXR

DXR is in the medium-term up 18% in 2 months and down -36% in 8 months.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Daxor Corporation, a medical device manufacturing company, offers biotech services in the United States. The company develops and markets BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients with heart failure, kidney failure, hypertension, and syncope; aid in fluid and blood transfusion management in the critical care unit; and aid in the diagnosis and treatment of disorders of red blood cell volume, including polycythemia and anemia, as well as used in pre-surgical evaluation of red blood cell volume. The company also provides cryobanking services, including blood and semen storage and related services. Daxor Corporation markets its products to hospitals and radiology imaging centers. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y-1216.53% Sales Growth - 4 Quarters -1.86% Sales Growth - Q/Q8.5% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-8.38% ROE-19.84% ROI
Current Ratio1.66 Quick Ratio1.65 Long Term Debt/Equity Debt Ratio1.36
Gross Margin54.91% Operating Margin-400.21% Net Profit Margin-496.96% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities300 K Cash From Investing Activities Cash From Operating Activities-300 K Gross Profit550 K
Net Profit-500 K Operating Profit470 K Total Assets46.05 M Total Current Assets
Total Current Liabilities Total Debt Total Liabilities21.47 M Total Revenue840 K
Technical Data
High 52 week19.52 Low 52 week4.3 Last close9.22 Last change-2.64%
RSI62.13 Average true range0.73 Beta0.12 Volume1.34 K
Simple moving average 20 days4.86% Simple moving average 50 days8.3% Simple moving average 200 days-10.48%
Performance Data
Performance Week-2.95% Performance Month17.3% Performance Quart-8.44% Performance Half-37.15%
Performance Year70.43% Performance Year-to-date12.44% Volatility daily4.48% Volatility weekly10.02%
Volatility monthly20.54% Volatility yearly71.16% Relative Volume69.25% Average Volume8.19 K
New High New Low


2019-09-11 08:00:00 | Daxor Corporation to Exhibit at the 23rd Annual Scientific Meeting of the Heart Failure Society of America

2019-09-04 08:00:00 | Daxor Corporation Announces a 38 Percent Rise in BVA-100 Cardiology Kit Sales and Net Gain of $498,111 for Six Months in Filing of Form N-CSR for June 30, 2019

2019-08-30 08:59:56 | How Do Daxor Corporation’s NYSEMKT:DXR Returns Compare To Its Industry?

2019-08-06 08:00:00 | Daxor Corporation Announces the Acquisition of the BVA-100® Blood Volume Analyzer by a Leading Academic Health Center in the Pacific Northwest

2019-06-18 08:00:00 | Daxor Corporation Announces New Research Initiative with Leading Hospital in the Southeast and the BVA-100® Blood Volume Diagnostic Test

2019-05-31 08:00:00 | Daxor Corporation to Present at the LD Micro 9th Annual Invitational on June 4th, 2019

2019-05-30 08:00:00 | Daxor Corporation Announces New Partnership with Leading Hospital in North Carolina to Integrate the BVA-100® Blood Volume Analyzer Diagnostic Test as Part of Standard Clinical Practice

2019-05-27 11:28:28 | Our Take On Daxor Corporation's NYSEMKT:DXR CEO Salary

2019-03-21 08:30:00 | Daxor Corporation Addresses and Corrects Erroneous Seeking Alpha Healthcare News Editor Article of March 20, 2019

2019-03-15 08:30:00 | Daxor Corporation to Present at the 31st Annual Roth Conference on March 19, 2019

2019-03-04 08:30:00 | Daxor Corporation Announces Rise in Kit Sales and Files Form N-CSR For 2018

2019-02-22 08:37:51 | New Research Further Demonstrates Clinical Utility and Improved Ease of Use with Daxor Corporation’s Blood Volume Analyzer BVA-100® in Critical Care

2019-02-13 08:30:00 | Daxor Corporation to Exhibit at the Society for Critical Care Medicine 48th Congress

2019-01-23 08:30:00 | Daxor Corporation Appoints Guido Manzo, Vice President of Sales

2019-01-10 08:30:00 | Daxor Corporation Announces Acquisition of BVA-100® Blood Volume Analyzer to Aspirus Wausau Hospital in Wisconsin

2018-11-13 08:30:00 | New Data Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer BVA-100 in Evaluation of Hypertension

2018-11-08 13:46:45 | New Data Demonstrating the Clinical Utility of Daxor’s BVA-100 in Hypertension Management to be Presented at the American Heart Association’s Scientific Sessions 2018 

2018-11-07 08:30:00 | Daxor Corporation Selected for U.S. Army Contract to Develop a Blood Volume Analyzer for Improvement of Combat Casualty Care

2018-11-01 08:30:00 | Daxor Corporation Initiates Strategic Collaboration with CHF Solutions, Inc. to Manage Patients with Fluid Overload

2018-11-01 08:30:00 | CHF Solutions Initiates Strategic Collaboration with Daxor Corporation to Assist in the Management of Patients with Fluid Overload

2018-10-30 08:30:00 | New Study Cites 82 Percent Mortality and 56 Percent Rehospitalization Reductions 30 Days After Therapy Guided by Daxor’s BVA-100 Blood Volume Analyzer in Acute Heart Failure Patients

2018-09-28 08:30:00 | Daxor Corporation Appoints Robert J. Michel as Chief Financial Officer

2018-09-25 08:30:00 | Daxor Corporation to Present at The MicroCap Conference on October 2, 2018

2018-09-17 08:30:00 | New Independent Data Further Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer BVA-100 Over Surrogate Measurements

2018-09-12 08:30:00 | Daxor Corporation to Exhibit at the 22nd Annual Scientific Meeting of the Heart Failure Society of America

2018-08-24 08:30:00 | Daxor Corporation Announces a 23 Percent Rise in BVA-100 Kit Sales in the Area of Cardiology and Filing of Form N-CSR for June 30, 2018

2018-08-20 08:30:00 | Newly Published Data Show Daxor Corporation's BVA-100 Is Superior To Formula-Based Estimates of Blood Volume In Assessing Patients With Heart Failure

2018-08-02 08:00:00 | Today’s Research Reports on Stocks to Watch: RXi Pharmaceuticals and Neurocrine Biosciences

2018-06-29 07:20:00 | Free Technical Research on Valeritas Holdings and Three More Medical Supplies Equities

2018-06-12 08:30:00 | Daxor Corporation Appoints Kathryn A. Kornafel Vice President of Marketing and Commercial Development

2018-06-04 08:30:00 | Daxor Corporation Initiates Study with Virginia Commonwealth University to Measure Improvement of Survival Rates Following Burn Surgery As A Result of Optimized Blood Volume Assessment

2018-05-30 08:30:00 | Daxor Corporation to Present at the LD Micro 8th Annual Invitational on June 4, 2018

2018-05-29 08:30:00 | Daxor Corporation Retains CORE IR as Investor Relations Firm of Record

2018-05-29 07:00:00 | Free Daily Technical Summary Reports on Endologix and Three Other Medical Supplies Stocks

2018-05-16 19:47:08 | Are Daxor Corporation’s NYSEMKT:DXR Interest Costs Too High?

2018-04-19 09:00:00 | A New Study Published in The Annals of Thoracic Surgery: Daxor’s BVA-100 Device Reveals Unexpected Blood Loss of 38% in Cardiac Surgical Patients Not Detected by Common Test in Use

2018-04-05 09:00:00 | Daxor to Present at The MicroCap Conference on April 9th and 10th in New York City at the Essex House

2018-03-22 09:00:00 | Daxor to Exhibit at the American Association of Heart Failure Nurses 2018 Advanced Heart Failure Symposium

2018-03-16 08:20:00 | Today’s Research Reports on Stocks to Watch: Daxor and Solid Biosciences

2018-03-15 14:00:00 | Daxor, Analysis of the BVA-100 Updates, Financial Data, and Product Review

2018-03-14 08:00:00 | New Data Showing Patient Care Individualized by Daxor’s Precision Blood Volume Analysis Reduces Heart Failure Readmissions by 56% and Mortality by over 80% Presented at the American College of Cardiology 2018 Annual Scientific Session

2018-03-09 11:55:02 | Daxor Corporation Announces Positive New Critical Care Research Highlighting Benefit from BVA Use; Daxor Corporation to Exhibit at the American College of Cardiology 2018 Annual Meeting NYSE MKT LLC: DXR

2018-03-08 12:56:01 | Daxor Corporation Announces Rise in Kit Sales, New Device Sale, and Filing of Form N-CSR for 2017 NYSE MKT LLC: DXR

2018-01-23 15:53:21 | Daxor Corporation NYSEMKT:DXR: Time For A Financial Health Check


2017-12-28 10:47:58 | Daxor Corp. : DXR-US: Dividend Analysis : December 21st, 2017 record date : By the numbers : December 28, 2017

2017-12-27 17:55:14 | Did Daxor Corporation’s NYSEMKT:DXR Earnings Growth Outperform The Industry?


2017-11-21 10:09:09 | Daxor Corporation DXR: Risks You Need To Consider Before Buying

2017-11-01 09:00:00 | Daxor Corporation Announces Share Buyback Program